- Home
- Equipment
- switzerland
- tumor cells
Show results for
Refine by
Tumor Cells Equipment Supplied In Switzerland
22 equipment items found
Manufactured by:AC BioScience SA based inEpalinges, SWITZERLAND
Our patented Beta-carboline derivative (ACB1801) is an actin dynamic modulator which induces cellular F-actin network remodeling (tumor reversal); this in turn translates into immuno-competency that allows the immune system to recognize tumor cells and thereby enhances the efficacy of checkpoint-inhibitor immune therapy. Immune ...
Manufactured by:Ferring Pharmaceuticals based inSaint-Prex, SWITZERLAND
FIRMAGON® (degarelix) is a treatment for men with advanced hormone-dependent prostate cancer. It has a novel mechanism of action that is different from traditional LHRH agonist therapy commonly used. Decreasing testosterone levels can cause the cancer cells to die, thus reducing the size of the tumour and delaying its growth. To date, FIRMAGON has been approved in 74 countries. ...
Manufactured by:MV BioTherapeutics SA based inBellinzona, SWITZERLAND
MV010/MV004, in cancer immunotherapy • Significant increase of tumor specific cytotoxic T cells infiltrating the tumor microenvironment by combining MV010/MV004 to anti-PD-L1 administration in murine models. • Significantly improved tumor eradication and resistance to subsequent grafting and improved survival in murine models. ...
Manufactured by:AC BioScience SA based inEpalinges, SWITZERLAND
Our product is a new-generation CAP6 that shows great promise as a highly effective treatment for lung cancer (NSCLC). Lung cancer is one of the most widely prevalent cancers, and one of the most difficult to treat. Eighty-one percent of patients treated for lung cancer die within five ...
Manufactured by:Sequana Medical NV based inSint-Denijs Westrem, BELGIUM
Ascites is also a common complication of certain late-stage cancers due to fluid build-up in the peritoneal cavity from a number of causes including draining of the lymph system. While life expectancy for many cancer patients with malignant ascites is short (less than 3 months), ovarian and breast cancer patients often have longer life expectancies. In 2018, the incidence in the U.S. and EU5 is ...
by:F. Hoffmann-La Roche Ltd. based inBasel, SWITZERLAND
Avastin is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A). With the initial approval in the United States for advanced colorectal cancer in 2004, Avastin became the first anti-angiogenic therapy made widely available for the treatment of patients with an advanced ...
by:CIS Pharma AG based inBubendorf, SWITZERLAND
CIS Pharma develops novel antibody-drug- conjugates (ADCs) based on our proprietary polymer carrier platform. Our polymers serve as carriers that are loaded with cytotoxic drugs, radioisotopes or other active entities. The carrier together with its cargo is conjugated to a target-specific antibody using site-directed linker chemistry, different from the linker chemistry used to attach the ...
Manufactured by:Araris Biotech AG based inAu, Zurich, SWITZERLAND
Araris Biotech AG, a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich, is pioneering the development of a novel, proprietary antibody-drug conjugate (ADC)-linker technology. Our linker platform enables payload attachment to ‘off-the-shelf’ antibodies in one step without needing to re-engineer or reduce antibodies, resulting in highly homogenous, stable and potent ...
by:F. Hoffmann-La Roche Ltd. based inBasel, SWITZERLAND
Alecensa is a highly selective, central nervous system-active, oral medicine used for the treatment of people with non-small cell lung cancer (NSCLC) whose tumours are identified as anaplastic lymphoma kinase (ALK)-positive. Alecensa is a tyrosine kinase inhibitor that targets ALK fusion proteins, preventing signalling within cancer cells to inhibit their growth and ...
Manufactured by:Auris Medical AG based inBasel, SWITZERLAND
The OligoPhore™ / SemaPhore™ technology has been extensively and successfully tested with various siRNA and mRNA sequences in numerous disease models in mice. For the development of our first proprietary drug product, AM-401 (OligoPhore™ siRNA targeting KRAS), we have initiated a program of IND-enabling ...
Manufactured by:Nuclidium AG based inBasel, SWITZERLAND
Nuclidium AG leverages the unique properties of copper radionuclides to advance precision radiotherapy and diagnostics. Their proprietary CuTrace™ platform combines copper nuclides with tumor-specific molecules, creating diagnostic and therapeutic pairs designed to optimize the safety and efficacy profile in cancer treatment. These radionuclides, including 61Cu for diagnostics and 67Cu for ...
by:T3 Pharmaceuticals AG based inBasel, SWITZERLAND
T3 Pharma has developed a proprietary cancer therapy platform based on regulating and harnessing the natural behaviours of live bacteria. The genetically engineered bacteria selectively target solid tumors, where they deliver chosen protein payloads into the ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
CD123 is expressed on multiple malignancies including BPDCN, AML, certain myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), B-cell acute lymphoid leukemia (B-ALL), hairy cell leukemia, and Hodgkin’s and certain non-Hodgkin’s lymphomas. In addition to expression on tumor bulk, CD123 ...
Manufactured by:Elthera AG based inSchlieren, SWITZERLAND
L1 cell adhesion molecule (L1CAM) is a cell surface protein which is aberrantly expressed in many different tumor types including pancreatic, ovarian, breast, lung, and colorectal cancer. L1CAM expression increases the malignancy of these tumors by promoting cellular proliferation, metastatic spread, ...
Manufactured by:InnoMedicus based inCham, SWITZERLAND
The Combat BRS System is an innovative bladder recirculation system designed to deliver. Combat BRS is an innovative bladder recirculation system for the treatment of non muscle invasive bladder carcinomas (NMIBC) with thermotherapy and cytostatic agents such as Mitomycin C, Epirubicin, etc. The patented system allows an effective heat exchange with a constant temperature of 43 ±0.5 ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
XPO1 has been shown to regulate nuclear export of many of the major tumor suppressor proteins and oncogenic cell growth regulators. Overexpression of XPO1 has been reported in many cancer types and is associated with aggressive tumor behavior and poor patient prognosis. Inhibition of XPO1 has been shown to restore tumor ...
Manufactured by:AC BioScience SA based inEpalinges, SWITZERLAND
Our medical objective is to validate and bring to clinical use, a novel approach to improve the treatment of metastatic pancreatic adenocarcinoma using a proangiogenic molecule S1P lyase inhibitor acting as a tumor vascular ...
Manufactured by:InSphero AG based inSchlieren, SWITZERLAND
An in vitro PDX model with in vivo-like heterogeneity. 3D InSight™ Tumor Microtissues from Patient-Derived Xenografts (PDX) are custom assay-ready 3D in vitro tumor models engineered to reflect complex tumor biology without the use of artificial matrices. Ideal for early stage cancer drug efficacy testing and screening appliciations, these advanced cancer models help bridge the gap between ...
by:CDR-Life based inSchlieren, SWITZERLAND
CDR-Life’s T cell engaging antibodies are potentially transformative in the field of cancer immunotherapies» Prof. Markus G. Manz, MD, Head of Medical Oncology and Hematology at University Hospital and University of Zurich, Switzerland. CDR-Life’s pipeline is based on it’s unique antibody fragment platform. It includes a series of highly cancer-targeted ...
Manufactured by:CanVirex AG based inBasel, SWITZERLAND
Oncolytic measles viruses as a multiplexed immune-modulating platform for cancer therapy. Cancer remains a medical and social burden worldwide despite several technological advances in the past decades. Conventional cancer treatments such as surgery, chemo-, or radiotherapy are restricted to local therapy or by dose-limiting toxicities and may induce drug resistance during treatment. In recent ...